GlaxoSmithKline bails out of its Fabry deal with Amicus

Slightly less than a year after GlaxoSmithKline ($GSK) and Amicus Therapeutics ($FOLD) reported a failure in their Phase III program for the Fabry disease drug Amigal, the pharma giant has bowed out of the development collaboration. GSK is handing over a check for $3 million to Amicus for a small equity stake and giving up its codevelopment and commercialization rights in exchange for a royalty on any future sales. Report

Suggested Articles

Pfizer will grab 50% of the COVID vaccine market to start, but competition—and not just in that market—will limit the upside, SVB Leerink said.

The FDA is reportedly mulling a warning letter for an Eli Lilly site where its COVID-19 antibody would be produced.

Transporting pharmaceutical products at <-60C for more than 96 hours has seemed an insurmountable challenge. TOWER’s solution has solved the problem.